Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipelineTARRYTOWN, N.Y., Jan. 30, 2024 Regeneron.
Akoustis Announces Pricing of Public Offering of $10 0 Million of Common Stock sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.
Board Co-Chair, CEO, CPO, and Other Company Management and Employees Investing $1 Million Charlotte, N.C., Jan. 25, 2024 Akoustis Technologies, Inc. , an integrated device manufacturer .